Cargando…
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer
Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA‐A*2402‐restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for pa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497926/ https://www.ncbi.nlm.nih.gov/pubmed/28498618 http://dx.doi.org/10.1111/cas.13278 |
_version_ | 1783248218238222336 |
---|---|
author | Obara, Wataru Sato, Fuminori Takeda, Kazuyoshi Kato, Renpei Kato, Yoichiro Kanehira, Mitsugu Takata, Ryo Mimata, Hiromitsu Sugai, Tamotsu Nakamura, Yusuke Fujioka, Tomoaki |
author_facet | Obara, Wataru Sato, Fuminori Takeda, Kazuyoshi Kato, Renpei Kato, Yoichiro Kanehira, Mitsugu Takata, Ryo Mimata, Hiromitsu Sugai, Tamotsu Nakamura, Yusuke Fujioka, Tomoaki |
author_sort | Obara, Wataru |
collection | PubMed |
description | Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA‐A*2402‐restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for patients with castration resistant prostate cancer (CRPC) using a CDCA1 peptide vaccination. Twelve patients having HLA‐A*2402 with CRPC after failure of docetaxel chemotherapy were enrolled. They received subcutaneous administration of the CDCA1 peptide as an emulsion with Montanide ISA51VG once a week in a dose‐escalation manner (doses of 1.0 or 3.0 mg/body, six patients received each dose). The primary endpoint was safety, and the secondary endpoints were the immunological and clinical responses. Vaccination with CDCA1 peptide was well tolerated without any serious adverse events. Peptide‐specific cytotoxic T lymphocyte (CTL) responses using ELISPOT assay and dextramer assay were observed in three patients receiving the 1.0 mg dose and five patients receiving the 3.0 mg dose. The median overall survival time was 11.0 months and specific CTL reacting to CDCA1 peptide were recognized in long‐surviving patients. CDCA1‐derived peptide vaccine treatment was tolerable and might effectively induce peptide‐specific CTLs for CRPC patients. This novel peptide vaccine therapy for CRPC appears promising. (ClinicalTrials.gov number, NCT01225471). |
format | Online Article Text |
id | pubmed-5497926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54979262017-07-10 Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer Obara, Wataru Sato, Fuminori Takeda, Kazuyoshi Kato, Renpei Kato, Yoichiro Kanehira, Mitsugu Takata, Ryo Mimata, Hiromitsu Sugai, Tamotsu Nakamura, Yusuke Fujioka, Tomoaki Cancer Sci Original Articles Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA‐A*2402‐restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for patients with castration resistant prostate cancer (CRPC) using a CDCA1 peptide vaccination. Twelve patients having HLA‐A*2402 with CRPC after failure of docetaxel chemotherapy were enrolled. They received subcutaneous administration of the CDCA1 peptide as an emulsion with Montanide ISA51VG once a week in a dose‐escalation manner (doses of 1.0 or 3.0 mg/body, six patients received each dose). The primary endpoint was safety, and the secondary endpoints were the immunological and clinical responses. Vaccination with CDCA1 peptide was well tolerated without any serious adverse events. Peptide‐specific cytotoxic T lymphocyte (CTL) responses using ELISPOT assay and dextramer assay were observed in three patients receiving the 1.0 mg dose and five patients receiving the 3.0 mg dose. The median overall survival time was 11.0 months and specific CTL reacting to CDCA1 peptide were recognized in long‐surviving patients. CDCA1‐derived peptide vaccine treatment was tolerable and might effectively induce peptide‐specific CTLs for CRPC patients. This novel peptide vaccine therapy for CRPC appears promising. (ClinicalTrials.gov number, NCT01225471). John Wiley and Sons Inc. 2017-06-23 2017-07 /pmc/articles/PMC5497926/ /pubmed/28498618 http://dx.doi.org/10.1111/cas.13278 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Obara, Wataru Sato, Fuminori Takeda, Kazuyoshi Kato, Renpei Kato, Yoichiro Kanehira, Mitsugu Takata, Ryo Mimata, Hiromitsu Sugai, Tamotsu Nakamura, Yusuke Fujioka, Tomoaki Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title | Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title_full | Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title_fullStr | Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title_full_unstemmed | Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title_short | Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer |
title_sort | phase i clinical trial of cell division associated 1 (cdca1) peptide vaccination for castration resistant prostate cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497926/ https://www.ncbi.nlm.nih.gov/pubmed/28498618 http://dx.doi.org/10.1111/cas.13278 |
work_keys_str_mv | AT obarawataru phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT satofuminori phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT takedakazuyoshi phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT katorenpei phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT katoyoichiro phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT kanehiramitsugu phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT takataryo phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT mimatahiromitsu phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT sugaitamotsu phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT nakamurayusuke phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer AT fujiokatomoaki phaseiclinicaltrialofcelldivisionassociated1cdca1peptidevaccinationforcastrationresistantprostatecancer |